E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
First-Line Diffuse Large B-Cell Lymphoma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10012855 |
E.1.2 | Term | Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare R-CHOP plus enzastaurin versus R-CHOP in terms of the elapsed progression-free survival (PFS) time measured in patients with intermediate and/or high-risk DLBCL receiving first-line treatment. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the study are as follows: • to compare R-CHOP plus enzastaurin versus R-CHOP in terms of complete response (CR) and/or unconfirmed CR (CRu) rate, and overall response rate (ORR) • to compare R-CHOP plus enzastaurin versus R-CHOP in terms of the 2-year PFS rate • to evaluate the PET-negative rates for each treatment arm • to investigate concordance between CT/MRI assessment and PET scan • to evaluate the following time-to-event efficacy variables for each treatment arm: - event-free survival (EFS) - overall survival (OS) - duration of complete response • to assess biomarkers relevant to enzastaurin and the disease state, as well as their correlation to clinical outcome • to evaluate toxicity and tolerability of R-CHOP plus enzastaurin |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients are eligible to be included in the study only if they meet all of the following criteria: [1] Have a histologically confirmed diagnosis of DLBCL based on the World Health Organization classification (Harris et al. 1999) at the time of original diagnosis. Pathology must be reviewed and confirmed prior to enrollment at the investigational site where the patient is entered. Patients with a prior history of an indolent lymphoma or a histological diagnosis of follicular Grade 3 lymphoma will not be eligible for enrollment. [2] Have received no prior chemotherapy. [3] Have an IPI score ≥2 at time of original diagnosis (Protocol Attachment S028.5). [4] Have a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology group (ECOG) scale (Protocol Attachment S028.4; Oken et al. 1982). [5] Have adequate organ function as follows: • Hepatic: total bilirubin ≤1.5 times the upper limit of normal (× ULN); alanine transaminase (ALT) and aspartate transaminase (AST) ≤1.5 × ULN, (≤5 × ULN, if liver involvement). • Renal: serum creatinine ≤1.5 × ULN • Adequate bone marrow reserve: platelets ≥75 × 109/L, absolute neutrophil count (ANC) ≥1.0 × 109/L, unless there is bone marrow involvement. [6] Have a normal left ventricular ejection fraction of ≥50% by echocardiography or nuclear medicine multi-gated (MUGA) scan. [7] Are at least 18 years of age. [8] Male and female patients with reproductive potential must use an approved contraceptive method, if appropriate (for example, intrauterine device [IUD], birth control pills, or barrier device) during and for 3 months after discontinuation of study treatment. Women with childbearing potential must have a negative serum pregnancy test ≤3 days prior to study enrollment. [9] Must agree to participate in PGx sampling and analysis. [10] Have an estimated life expectancy of at least 12 weeks. [11] Must sign an informed consent document (or legal representative has given informed consent). [12] Exhibit patient compliance and geographic proximity that allow for adequate follow-up. |
|
E.4 | Principal exclusion criteria |
Patients will be excluded from the study if they meet any of the following criteria: [13] Have received treatment within the last 30 days with a drug (not including enzastaurin) that has not received regulatory approval for any indication at the time of study entry. [14] Are receiving concurrent administration of any other systemic anticancer therapy. [15] Are pregnant or breastfeeding. [16] Are unable to swallow tablets. [17] Are unable to discontinue use of carbamazepine, phenobarbital, and phenytoin at least 14 days prior to study enrollment (Protocol Attachment S028.3). [18] Have a serious concomitant systemic disorder, including active bacterial or fungal infection, incompatible with the study (at the discretion of the investigator). [19] Have human immunodeficiency virus (HIV) associated lymphomas. [20] Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV (Protocol Attachment S028.6). [21] Have a prior malignancy (other than DLBCL, or adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer), unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. [22] Have central nervous system (CNS) metastases. A screening CT or MRI before enrollment in the absence of a clinical suspicion of brain metastases is not required. [23] Have previously received enzastaurin therapy in any other clinical trial |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint for this study is progression-free survival |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 6 |